Cargando…
In vivo Genome Editing Therapeutic Approaches for Neurological Disorders: Where Are We in the Translational Pipeline?
In vivo genome editing tools, such as those based on CRISPR, have been increasingly utilized in both basic and translational neuroscience research. There are currently nine in vivo non-CNS genome editing therapies in clinical trials, and the pre-clinical pipeline of major biotechnology companies dem...
Autores principales: | Lubroth, Pablo, Colasante, Gaia, Lignani, Gabriele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930815/ https://www.ncbi.nlm.nih.gov/pubmed/33679313 http://dx.doi.org/10.3389/fnins.2021.632522 |
Ejemplares similares
-
ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?
por: Mejzini, Rita, et al.
Publicado: (2019) -
Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go
por: De Maria Marchiano, Ruggero, et al.
Publicado: (2021) -
Animal Models of Neurological Disorders: Where Are We Now?
por: Panthi, Sandesh, et al.
Publicado: (2023) -
Mesenchymal Stromal Cells’ Therapy for Polyglutamine Disorders: Where Do We Stand and Where Should We Go?
por: Barros, Inês, et al.
Publicado: (2020) -
Editorial on the Special Issue “Botulinum Toxin for the Treatment of Neurological Disorders: Where We Are and Where We Need to Go”
por: Jog, Mandar, et al.
Publicado: (2022)